Neuro Vigor Therapeutics and our collaborators are pioneering new drugs to inhibit toxic molecules called reactive aldehyde species (RAS), which have been implicated in the pathogenesis of multiple diseases, neuropathic pain and trauma.
RAS are a by-product of at least five biological pathways, (including lipid peroxidation, metabolism of polyamines and glucose, myeloperoxidase-induced breakdown of threonine, chemotherapies). Environmental sources of RAS include air pollution, auto exhaust, cigarette /e-cigarette smoking, fried foods, and alcoholic beverages.
RAS covalently bind to cellular biomolecules such as proteins, causing misfolding, aggregation, and dysfunction. They also increase oxidative stress, incite inflammation, disrupt and damage mitochondria, alter and destroy DNA, deplete endogenous antioxidants, and stimulate pain. Acrolein is the most potent RAS and is responsible for >80% of RAS protein adducts. RAS exert damage via a vicious cycle in which they initiate damaging biochemical cascades and inflammation that in turn generate more RAS. Research demonstrates that RAS are significantly elevated in disease and trauma.
Reducing RAS has high therapeutic potential across a broad array of clinical applications.